The main cause of anterior-segment neovascularization in neovascular glaucoma (NVG) is posterior-segment ischemia. Retinal ischemia triggers the release of angiogenic factors such as VEGFs which lead to neovascularization of retina, iris, and angle. In the management of NVG, it is important to treat the underlying ischemic changes in the retina. Intravitreal anti-VEGFs reduces the posterior-segment ischemia and inhibits the release of angiogenic factors which cause regression of existing new vessels and prevent further neovascularization. [2] Vitreous body serves as a reservoir for anti-VEGFs and ensures prolonged effect of anti-VEGF agents. Therefore, vitreous is the preferred location for anti-VEGF injections in NVG. Furthermore, data from literature have shown that monthly intravitreal injection for several months is safe for the retina and anterior segment. However, intravitreal injections need an anterior-chamber paracentesis to reduce sudden increase in intraocular pressure (IOP) which can place the optic nerve at further risk of damage.
On the other hand, intracameral anti-VEGFs will not cause sudden increase in IOP, [3] can be performed in the presence of media opacities, can safe to corneal endothelium, and have fewer vitreoretinal complications. However, intracameral injection shows shorter half-life and duration of effect than intravitreal injection. [2] In addition, as the drug cannot diffuse into the posterior segment, intracameral injections will not reduce the retinal ischemia and release of angiogenic factors.
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